Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on mens and womens health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Aceruss product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is headquartered in Mississauga, Ontario, Canada.
Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on mens and womens health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Aceruss product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is headquartered in Mississauga, Ontario, Canada.
Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 4
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 14
Trimel Pharma Enters Into Co-Development Agreement With European Company 14
Licensing Agreements 15
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 15
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 15
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 16
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Licensing Agreement with Medinova 19
Equity Offering 19
Acerus Pharma Raises USD2 Million in Private Placement of Shares 19
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 21
Trimel Pharma Announces Full Exercise Of Underwriters Option For Public Offering Of Shares For US$45 Million 22
Trimel Pharma Announces Rights Offering Of Shares 23
Trimel Pharma Completes Public Offering Of Units For US$13 Million 24
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 25
Debt Offering 26
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 26
Acquisition 27
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 27
Acerus Pharmaceuticals Corp - Key Competitors 28
Key Employees 29
Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 31
Nov 02, 2016: Acerus Reports Third Quarter 2016 Financial Results 33
Aug 09, 2016: Acerus Reports Second Quarter 2016 Results 35
May 04, 2016: Acerus Reports First Quarter 2016 Results and Provides Business Update 36
Mar 02, 2016: Acerus Reports Fourth Quarter and Full Year 2015 Financial Results 38
Corporate Communications 40
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 40
Nov 01, 2016: Acerus Announces Appointment of Tricia Symmes as Chief Operating Officer 41
Jul 21, 2016: Acerus Appoints Mr. Luc Mainville to Its Board of Directors 42
Mar 24, 2016: Acerus Announces Departure of Dr. Michael Bumby 43
Legal and Regulatory 44
May 17, 2016: Acerus Provides Update on Litigation 44
Apr 08, 2016: Acerus comments on statement of claim 45
Apr 05, 2016: Litigation Against Acerus Pharmaceuticals Continues 46
Mar 09, 2016: Eugene Melnyk Initiates Legal Proceedings Against Acerus Pharmaceuticals, its Chairman, Ihor Ihnatowycz, and Others 47
Other Significant Developments 48
Dec 21, 2016: Acerus Comments on Decision Regarding Litigation 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List Of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 14
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 15
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 15
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 16
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Licensing Agreement with Medinova 19
Acerus Pharma Raises USD2 Million in Private Placement of Shares 19
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 21
Trimel Pharma Announces Full Exercise Of Underwriters Option For Public Offering Of Shares For US$45 Million 22
Trimel Pharma Announces Rights Offering Of Shares 23
Trimel Pharma Completes Public Offering Of Units For US$13 Million 24
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 25
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 26
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 27
Acerus Pharmaceuticals Corp, Key Competitors 28
Acerus Pharmaceuticals Corp, Key Employees 29
Acerus Pharmaceuticals Corp, Subsidiaries 30
List Of Figures
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
RELATED REPORTS
Phio Pharmaceuticals Corp (RXII) - Financial and Strategic SWOT Analysis Review
Phio Pharmaceuticals Corp (Phio Pharmaceuticals), formerly known as RXi Pharmaceuticals Corp, is a biotechnology company. It discovers, develops and commercializes immuno-oncology therapeutics based RNAi platform to treat cancer. Its product
View ReportAdamis Pharmaceuticals Corp (ADMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc is a biopharmaceutical company that offers therapies. The company develops and commercializes products in the therapeutic areas of allergy and respiratory diseases.
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
